Allergic asthma
Conditions
Interventions
experimental group:Omazumab
control group:ICS
Sponsors
Guangzhou Women and Children's Medical Center
Eligibility
Sex/Gender
All
Age
6 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of allergic asthma; 2. Aged 6 to 18 years; 3. Investigator-diagnosed allergic asthma eligible for treatment with omalizumab, with coexisting conditions including allergic rhinitis, atopic dermatitis, nasal polyps, chronic urticaria, and food allergy; 4. The informed consent form have been signed. 5. Able to comply with the requirements of the trial.
Exclusion criteria
Exclusion criteria: 1. According to the judgment of the researchers, patients who can't tolerate the treatment of this program; 2. Patients who are allergic to the drugs in the program; 3. Patients who are unable to receive regular treatment and regular follow-up due to psychological, family and geographical reasons; 4. Patients with severe infection, internal diseases, important organ dysfunction and mental disorders; 5. Patients who have undergone other clinical trials within three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Global Evaluation of Treatment Effectiveness, GETE;Children Asthma Control Test, C-ACT; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Serious adverse events; | — |
Countries
China
Contacts
Public ContactChunhui He
Guangzhou Women and Children's Medical Center
Outcome results
None listed